What to expect after natalizumab cessation in a real-life setting.

S Salhofer-Polanyi; A Baumgartner; Jörg Kraus; E Maida; M Schmied; F Leutmezer

doi:10.1111/ane.12250

What to expect after natalizumab cessation in a real-life setting.

S Salhofer-Polanyi, A Baumgartner, Jörg Kraus (Co-author), E Maida, M Schmied, F Leutmezer

Department of Neurology

Research output: Contribution to journal › Original Article › peer-review

26 Citations (Web of Science)

Original language	English
Pages (from-to)	97-102
Journal	ACTA NEUROLOGICA SCANDINAVICA
Volume	130
Issue number	2
DOIs	https://doi.org/10.1111/ane.12250
Publication status	Published - 2014

Keywords

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
RECONSTITUTION INFLAMMATORY SYNDROME
RELAPSING MULTIPLE-SCLEROSIS
PLACEBO-CONTROLLED TRIAL
DISCONTINUING NATALIZUMAB
DRUG HOLIDAY
MS PATIENTS
THERAPY
WITHDRAWAL
RISK

Access to Document

10.1111/ane.12250

Cite this

Salhofer-Polanyi, S., Baumgartner, A., Kraus, J., Maida, E., Schmied, M., & Leutmezer, F. (2014). What to expect after natalizumab cessation in a real-life setting. ACTA NEUROLOGICA SCANDINAVICA , 130(2), 97-102. https://doi.org/10.1111/ane.12250

Salhofer-Polanyi, S ; Baumgartner, A ; Kraus, Jörg et al. / What to expect after natalizumab cessation in a real-life setting. In: ACTA NEUROLOGICA SCANDINAVICA 2014 ; Vol. 130, No. 2. pp. 97-102.

@article{0824763778bf417593583e39e6666f3f,

title = "What to expect after natalizumab cessation in a real-life setting.",

keywords = "PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, RECONSTITUTION INFLAMMATORY SYNDROME, RELAPSING MULTIPLE-SCLEROSIS, PLACEBO-CONTROLLED TRIAL, DISCONTINUING NATALIZUMAB, DRUG HOLIDAY, MS PATIENTS, THERAPY, WITHDRAWAL, RISK",

author = "S Salhofer-Polanyi and A Baumgartner and J{\"o}rg Kraus and E Maida and M Schmied and F Leutmezer",

year = "2014",

doi = "10.1111/ane.12250",

language = "English",

volume = "130",

pages = "97--102",

journal = "ACTA NEUROLOGICA SCANDINAVICA ",

issn = "0001-6314",

number = "2",

}

Salhofer-Polanyi, S, Baumgartner, A, Kraus, J, Maida, E, Schmied, M & Leutmezer, F 2014, 'What to expect after natalizumab cessation in a real-life setting.', ACTA NEUROLOGICA SCANDINAVICA , vol. 130, no. 2, pp. 97-102. https://doi.org/10.1111/ane.12250

What to expect after natalizumab cessation in a real-life setting. / Salhofer-Polanyi, S; Baumgartner, A; Kraus, Jörg (Co-author) et al.
In: ACTA NEUROLOGICA SCANDINAVICA , Vol. 130, No. 2, 2014, p. 97-102.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - What to expect after natalizumab cessation in a real-life setting.

AU - Salhofer-Polanyi, S

AU - Baumgartner, A

AU - Kraus, Jörg

AU - Maida, E

AU - Schmied, M

AU - Leutmezer, F

PY - 2014

Y1 - 2014

KW - PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

KW - RECONSTITUTION INFLAMMATORY SYNDROME

KW - RELAPSING MULTIPLE-SCLEROSIS

KW - PLACEBO-CONTROLLED TRIAL

KW - DISCONTINUING NATALIZUMAB

KW - DRUG HOLIDAY

KW - MS PATIENTS

KW - THERAPY

KW - WITHDRAWAL

KW - RISK

U2 - 10.1111/ane.12250

DO - 10.1111/ane.12250

M3 - Original Article

C2 - 24720783

SN - 0001-6314

VL - 130

SP - 97

EP - 102

JO - ACTA NEUROLOGICA SCANDINAVICA

JF - ACTA NEUROLOGICA SCANDINAVICA

IS - 2

ER -

Salhofer-Polanyi S, Baumgartner A, Kraus J, Maida E, Schmied M, Leutmezer F. What to expect after natalizumab cessation in a real-life setting. ACTA NEUROLOGICA SCANDINAVICA . 2014;130(2):97-102. doi: 10.1111/ane.12250